Physician profile
Meen Misra
NPI 1336134105
$588.52
in general payments reported to CMS, 2019-2025
12 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.93 · 2020: $32.38 · 2021: $12.23 · 2022: $33.11 · 2023: $171 · 2024: $134 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $127.28 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $72.51 | 2024-2025 | Veozah |
| Novo Nordisk INC | $71.23 | 2024-2025 | Ozempic |
| Abbott Laboratories | $68.00 | 2023-2024 | Proclaim, Jot Dx |
| Amarin Pharma, INC. | $48.45 | 2019 | |
| Lilly USA, LLC | $47.29 | 2022-2024 | Zepbound |
| Daiichi Sankyo INC. | $37.37 | 2025 | Injectafer |
| Amgen INC. | $33.54 | 2025 | Evenity |
| Boston Scientific Corporation | $32.38 | 2020 | |
| Abbvie INC. | $24.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meen Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.